Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Liver-Directed AAV Gene Therapy for Gaucher Disease

Carlos J Miranda, PhD, Miriam Canavese, PhD, Elisa Chisari, MS, Jalpa Pandya, MPhil, Clement Cocita, PhD, Maria Portillo, MRes, Jenny McIntosh, PhD, Azadeh Kia, PhD, Jonathan H. Foley, PhD, Allison Dane, PhD, Jey M Jeyakumar, PhD, Rose Sheridan, PhD, Romuald Corbau, Amit C. Nathwani, MD PhD

Blood (2019) 134 (Supplement_1): 3354.

https://doi.org/10.1182/blood-2019-124280

Published: 2019

Journal Articles

Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma

Loredana Santo, Teru Hideshima, Andrew L. Kung, Jen-Chieh Tseng, David Tamang, Min Yang, Matthew Jarpe, John H. van Duzer, Ralph Mazitschek, Walter C. Ogier, Diana Cirstea, Scott Rodig, Homare Eda, Tyler Scullen, Miriam Canavese, James Bradner, Kenneth C. Anderson, Simon S. Jones, Noopur Raje

Blood (2012) 119 (11): 2579–2589.

https://doi.org/10.1182/blood-2011-10-387365

Published: 2012

Includes: Supplemental data

Journal Articles

Increased Sclerostin Secretion in Multiple Myeloma Results in Stimulation of Osteoclastogenesis and Inhibition of Osteoblastogenesis

Homare Eda, MD, PhD, Loredana Santo, MD, Diana D. Cirstea, MD, Samantha Pozzi, MD, Miriam Canavese, PhD, Tyler A. Scullen, BA, Sonia Vallet, MD, Noopur S. Raje, MD

Blood (2011) 118 (21): 1819.

https://doi.org/10.1182/blood.V118.21.1819.1819

Published: 2011

Journal Articles

Selective HDAC6 Inhibition Via ACY-1215, Either Alone or in Combination with Bortezomib, Restores Osteoblast Function and Suppresses Osteoclast Differentiation in Multiple Myeloma

Loredana Santo, MD, Teru Hideshima, MD, PhD, Andrew L. Kung, MD, PhD, Jen-Chieh Tseng, PhD, David Tamang, PhD, Min Yang, PhD, Matthew Jarpe, PhD, John H. van Duzer, PhD, Ralph Mazitschek, PhD, Diana Cirstea, MD, Homare Eda, MD, PhD, Tyler A. Scullen, BA, Scott Rodig, MD, PhD, Miriam Canavese, PhD, James Bradner, MD, Kenneth C Anderson, MD, Simon Jones, PhD, Noopur S. Raje, MD

Blood (2011) 118 (21): 2908.

https://doi.org/10.1182/blood.V118.21.2908.2908

Published: 2011

Journal Articles

Pharmacodynamic and Pharmacokinetic Properties of a Novel and Selective HDAC6 Inhibitor, ACY-1215, in Combination with Bortezomib in Multiple Myeloma

Loredana Santo, MD, Teru Hideshima, MD, PhD, Andrew L. Kung, MD, PhD, Jen-Chieh Tseng, PhD, David Tamang, PhD, Min Yang, PhD, Matthew Jarpe, PhD, John H. van Duzer, PhD, Ralph Mazitschek, PhD, Walter C Ogier, Diana D. Cirstea, MD, Scott Rodig, MD, PhD, Homare Eda, MD, PhD, Tyler A. Scullen, BA, Miriam Canavese, PhD, James E. Bradner, MD, Kenneth C Anderson, MD, Simon Jones, PhD, Noopur S. Raje, MD

Blood (2011) 118 (21): 2912.

https://doi.org/10.1182/blood.V118.21.2912.2912

Published: 2011

Journal Articles

DEPTOR Is a Regulator of Response to mTOR Kinase Inhibitors in Multiple Myeloma

Diana Cirstea, MD, Teru Hideshima, MD, PhD, Loredana Santo, MD, Homare Eda, MD, PhD, Miriam Canavese, PhD, Tyler A. Scullen, BA, Anuj K. Mahindra, MD, Gullu Gorgun, PhD, Yiguo Hu, MD, PhD, Naoya Mimura, MD, PhD, Claire Fabre, MD, PhD, Jiro Minami, MD, PhD, Hiroto Ohguchi, MD, PhD, Kenneth C. Anderson, MD, Sylvie M Guichard, PharmD, PhD, Noopur S. Raje, MD

Blood (2011) 118 (21): 2916.

https://doi.org/10.1182/blood.V118.21.2916.2916

Published: 2011

Journal Articles

Targeting Bruton's Tyrosine Kinase As a Novel Approach to Inhibit Osteoclast Function in Multiple Myeloma

Homare Eda, MD, PhD, Loredana Santo, MD, Diana D. Cirstea, MD, Samantha Pozzi, MD, Miriam Canavese, PhD, Tyler A. Scullen, BA, Sonia Vallet, MD, Erica Evans, PhD, Juswinder Singh, PhD, Noopur S. Raje, MD

Blood (2011) 118 (21): 2882.

https://doi.org/10.1182/blood.V118.21.2882.2882

Published: 2011

NARROW

Liver-Directed AAV Gene Therapy for Gaucher Disease

Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma

Increased Sclerostin Secretion in Multiple Myeloma Results in Stimulation of Osteoclastogenesis and Inhibition of Osteoblastogenesis

Selective HDAC6 Inhibition Via ACY-1215, Either Alone or in Combination with Bortezomib, Restores Osteoblast Function and Suppresses Osteoclast Differentiation in Multiple Myeloma

Pharmacodynamic and Pharmacokinetic Properties of a Novel and Selective HDAC6 Inhibitor, ACY-1215, in Combination with Bortezomib in Multiple Myeloma

DEPTOR Is a Regulator of Response to mTOR Kinase Inhibitors in Multiple Myeloma

Targeting Bruton's Tyrosine Kinase As a Novel Approach to Inhibit Osteoclast Function in Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Liver-Directed AAV Gene Therapy for Gaucher Disease

Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma

Increased Sclerostin Secretion in Multiple Myeloma Results in Stimulation of Osteoclastogenesis and Inhibition of Osteoblastogenesis

Selective HDAC6 Inhibition Via ACY-1215, Either Alone or in Combination with Bortezomib, Restores Osteoblast Function and Suppresses Osteoclast Differentiation in Multiple Myeloma

Pharmacodynamic and Pharmacokinetic Properties of a Novel and Selective HDAC6 Inhibitor, ACY-1215, in Combination with Bortezomib in Multiple Myeloma

DEPTOR Is a Regulator of Response to mTOR Kinase Inhibitors in Multiple Myeloma

Targeting Bruton's Tyrosine Kinase As a Novel Approach to Inhibit Osteoclast Function in Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only